> Detailanzeige

Rostad, Christina A.; Chahroudi, Ann; Mantus, Grace; Lapp, Stacey A.; Teherani, Mehgan; Macoy, Lisa; Tarquinio, Keiko M.; Basu, Rajit K.; Kao, Carol; Linam, W. Matthew; Zimmerman, Matthew G.; Shi, Pei-Yong; Menachery, Vineet D.; Oster, Matthew E.; Edupuganti, Srilatha; Anderson, Evan J.; Suthar, Mehul S.; Wrammert, Jens; Jaggi, Preeti

Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)
  • Beteiligte: Rostad, Christina A.; Chahroudi, Ann; Mantus, Grace; Lapp, Stacey A.; Teherani, Mehgan; Macoy, Lisa; Tarquinio, Keiko M.; Basu, Rajit K.; Kao, Carol; Linam, W. Matthew; Zimmerman, Matthew G.; Shi, Pei-Yong; Menachery, Vineet D.; Oster, Matthew E.; Edupuganti, Srilatha; Anderson, Evan J.; Suthar, Mehul S.; Wrammert, Jens; Jaggi, Preeti
  • Erschienen: American Academy of Pediatrics (AAP), 2020
  • Erschienen in: Pediatrics
  • Sprache: Englisch
  • DOI: 10.1542/peds.2020-018242
  • ISSN: 0031-4005; 1098-4275
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>OBJECTIVES:</jats:title> <jats:p>We aimed to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological responses in children hospitalized with multisystem inflammatory syndrome in children (MIS-C) compared with those with coronavirus disease 2019 (COVID-19), those with Kawasaki disease (KD), and hospitalized pediatric controls.</jats:p> </jats:sec> <jats:sec> <jats:title>METHODS:</jats:title> <jats:p>From March 17, 2020, to May 26, 2020, we prospectively identified hospitalized children with MIS-C (n = 10), symptomatic COVID-19 (n = 10), and KD (n = 5) and hospitalized controls (n = 4) at Children’s Healthcare of Atlanta. With institutional review board approval, we obtained prospective and residual blood samples from these children and measured SARS-CoV-2 spike receptor-binding domain (RBD) immunoglobulin M and immunoglobulin G (IgG), full-length spike IgG, and nucleocapsid protein antibodies using quantitative enzyme-linked immunosorbent assays and SARS-CoV-2 neutralizing antibodies using live-virus focus-reduction neutralization assays. We statistically compared the log-transformed antibody titers among groups and performed linear regression analyses.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS:</jats:title> <jats:p>All children with MIS-C had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated with full-length spike IgG antibodies (R2 = 0.956; P &amp;lt; .001), nucleocapsid protein antibodies (R2 = 0.846; P &amp;lt; .001), and neutralizing antibodies (R2 = 0.667; P &amp;lt; .001). Children with MIS-C had significantly higher SARS-CoV-2 RBD IgG antibody titers (geometric mean titer 6800; 95% confidence interval 3495–13 231) than children with COVID-19 (geometric mean titer 626; 95% confidence interval 251–1563; P &amp;lt; .001), children with KD (geometric mean titer 124; 95% confidence interval 91–170; P &amp;lt; .001), and hospitalized controls (geometric mean titer 85; P &amp;lt; .001). All children with MIS-C also had detectable RBD immunoglobulin M antibodies, indicating recent SARS-CoV-2 infection. RBD IgG titers correlated with the erythrocyte sedimentation rate (R2 = 0.512; P &amp;lt; .046) and with hospital (R2 = 0.548; P = .014) and ICU lengths of stay (R2 = 0.590; P = .010).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS:</jats:title> <jats:p>Quantitative SARS-CoV-2 serology may have a role in establishing the diagnosis of MIS-C, distinguishing it from similar clinical entities, and stratifying risk for adverse outcomes.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang